Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Abstract

<jats:title>Abstract</jats:title><jats:p>Background: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.</jats:p>

The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

“…Although HA/CaS compound is naturally radiopaque, the manufacturer states CERAMENT -the bone gra substitute used in our study -provides enhanced radiopacity due to radiopaque agent iohexol. e claim is backed by two authors reporting good perioperative radio visibility of the void ller during the operation [8,15]. Surgeons state other advantages of its users such as reliable injectability, early unrestricted activity, and fast remodeling to bone [8,12,15].…”

“…e claim is backed by two authors reporting good perioperative radio visibility of the void ller during the operation [8,15]. Surgeons state other advantages of its users such as reliable injectability, early unrestricted activity, and fast remodeling to bone [8,12,15].…”

“…Especially, when the lesion grows rapidly, is symptomatic, and is radiologically unclear, the biopsy is indicated. [8] Treatment modality is chosen based on fracture risk and the presence of symptoms [5]. Small, asymptomatic UBCs found incidentally may be treated with observation alone [5,6].…”

“…Calcium sulfate acts as a resorbable carrier for hydroxyapatite. Hydroxyapatite has a slow resorption rate, high osteoconductivity that promotes bone in-growth and gives long-term structural support to newly formed bone [8]. is method is suitable for percutaneous curettage and gra ing [12].…”

Management of the Cavity After Removal of Giant Cell Tumor of the Bone

“…The combination of different inorganic materials, inorganic and organic, inorganic materials, and bone induction factors as well as organic materials and bone induction factors has gradually appeared. Kotrych et al ( 105 ) reported that the application of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) achieved good clinical effects. Hattori et al ( 106 ) found that HA/TCP was more bioresorbable and osteoconductive than HA or AWGC.…”